Physician profile
James Mcdaniel Reed
NPI 1235145459
$3,124.59
in general payments reported to CMS, 2019-2025
25 companies · $647 in 2025
The $647 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $766 · 2023: $425 · 2024: $977 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $717.70 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $564.38 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $249.89 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $188.32 | 2022-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $173.93 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $158.27 | 2021-2023 | |
| Exact Sciences Corporation | $147.57 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $133.05 | 2023-2025 | Veozah, Myrbetriq |
| Inspire Medical Systems, INC. | $123.52 | 2023-2024 | Inspire |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $93.03 | 2022-2025 | Breztri |
| Amgen INC. | $85.87 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.24 | 2021-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $69.09 | 2022-2023 | |
| Shield Therapeutics INC | $47.20 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.28 | 2022-2024 | Rexulti |
| Amarin Pharma, INC. | $39.65 | 2021-2022 | |
| Boston Scientific Corporation | $19.41 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $16.03 | 2021 | |
| Daiichi Sankyo INC. | $14.62 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.33 | 2022 | |
| Genentech USA, INC. | $13.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.77 | 2022 | |
| Eisai INC. | $11.85 | 2022 | |
| Cequr Corporation | $3.50 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.